Open Access<p>ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway</p>
Author(s) -
Guangliang Li,
Jing Zhang,
Zhenzhen Xu,
Zhongqi Li
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s226410
Subject(s) - gene knockdown , tamoxifen , cancer research , mtt assay , mcf 7 , cell growth , in vivo , mapk/erk pathway , breast cancer , cell culture , transfection , western blot , in vitro , biology , chemistry , cancer , signal transduction , medicine , microbiology and biotechnology , biochemistry , genetics , human breast , gene
Acquired tamoxifen resistance is one of the major barriers to the successful treatment of breast cancer. Recently, overexpression of ERα36 was demonstrated to be a potential mechanism for the generation of acquired tamoxifen resistance. This study aims to evaluate the possibility of ERα36 being a therapeutic target for tamoxifen-resistant breast cancer.